Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-13.35 Insider Own50.78% Shs Outstand18.98M Perf Week-11.98%
Market Cap6.89M Forward P/E- EPS next Y- Insider Trans125.61% Shs Float9.34M Perf Month6.76%
Income-82.35M PEG- EPS next Q- Inst Own27.00% Short Float / Ratio4.60% / 0.60 Perf Quarter-94.18%
Sales0.00M P/S- EPS this Y- Inst Trans15.32% Short Interest0.43M Perf Half Y-82.80%
Book/sh-1.42 P/B- EPS next Y- ROA-153.98% Target Price10.00 Perf Year-99.06%
Cash/sh0.91 P/C0.40 EPS next 5Y- ROE-6232.76% 52W Range0.30 - 41.59 Perf YTD-98.87%
Dividend- P/FCF- EPS past 5Y-4.69% ROI- 52W High-99.13% Beta2.05
Dividend %- Quick Ratio0.48 Sales past 5Y0.00% Gross Margin- 52W Low20.72% ATR0.13
Employees66 Current Ratio0.48 Sales Q/Q- Oper. Margin0.00% RSI (14)31.15 Volatility10.20% 21.37%
OptionableNo Debt/Eq- EPS Q/Q87.43% Profit Margin- Rel Volume0.31 Prev Close0.38
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume712.14K Price0.36
Recom5.00 SMA20-16.77% SMA50-74.20% SMA200-92.04% Volume218,825 Change-5.69%
Date Action Analyst Rating Change Price Target Change
Nov-01-21Upgrade Chardan Capital Markets Neutral → Buy $12
Jun-23-21Initiated Cantor Fitzgerald Overweight $28
Apr-12-21Upgrade Jefferies Hold → Buy $11 → $18
Dec-23-20Initiated JMP Securities Mkt Outperform $27
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Nov-22-23 07:00AM
Nov-14-23 03:57PM
Nov-02-23 08:40AM
Oct-18-23 11:21AM
09:52AM Loading…
Oct-17-23 07:00AM
Aug-14-23 07:30AM
Aug-10-23 02:27PM
Jul-18-23 03:00AM
Jul-12-23 07:30AM
Jul-10-23 07:30AM
Jun-29-23 09:00AM
12:00PM Loading…
May-17-23 12:00PM
May-16-23 06:00AM
May-10-23 08:42AM
Apr-26-23 03:51PM
Mar-20-23 10:46PM
Mar-16-23 10:23PM
Mar-09-23 06:00AM
Mar-01-23 09:35AM
Feb-27-23 06:00AM
Feb-13-23 09:35AM
Feb-01-23 01:56PM
12:53PM Loading…
Jan-24-23 06:48AM
Jan-11-23 04:15PM
Dec-16-22 06:01AM
Dec-01-22 07:40AM
Nov-15-22 04:01PM
Nov-14-22 05:27PM
Nov-08-22 06:00AM
Sep-07-22 01:00AM
Sep-01-22 05:15PM
Aug-11-22 11:00PM
Aug-08-22 09:33AM
Aug-05-22 06:00AM
Jul-18-22 06:00AM
Jun-24-22 08:01AM
May-25-22 08:37AM
May-12-22 10:47AM
Apr-21-22 06:00AM
Apr-14-22 11:22AM
Apr-06-22 06:00AM
Mar-26-22 12:00PM
Mar-24-22 01:30PM
Mar-17-22 07:00AM
Mar-07-22 06:00AM
Mar-02-22 08:50AM
Feb-28-22 09:00AM
Feb-24-22 07:55AM
Feb-17-22 07:00AM
Feb-15-22 10:05AM
Feb-11-22 12:00PM
Feb-07-22 07:00AM
Jan-17-22 07:00AM
Jan-04-22 07:00AM
Dec-14-21 07:00AM
Nov-09-21 07:00AM
Oct-28-21 07:01PM
Oct-21-21 07:00AM
Oct-18-21 08:49AM
Oct-13-21 10:47AM
Sep-29-21 03:37AM
Sep-28-21 12:38PM
Sep-27-21 12:11PM
Sep-20-21 07:00AM
Sep-09-21 07:00AM
Sep-08-21 08:30AM
Sep-07-21 07:00AM
Aug-06-21 08:46AM
Jul-31-21 05:31AM
Jul-29-21 07:00AM
Jul-22-21 07:00AM
Jul-14-21 04:01PM
Jun-21-21 06:50PM
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bodmer MarkCSO, President of R&DNov 08Sale0.333,1631,04425,732Nov 08 08:32 PM
McHale DuncanChief Medical OfficerNov 08Sale0.333,1031,02416,984Nov 08 08:32 PM
Thorell MarellaChief Financial OfficerNov 08Sale0.331,81159822,259Nov 08 08:31 PM
GILL SIMBAPresident & CEONov 08Sale0.331725717,758Nov 08 08:31 PM
McHale DuncanChief Medical OfficerNov 02Sale0.336,8542,26213,587Nov 03 04:11 PM
Bodmer MarkCSO, President of R&DNov 02Sale0.336,8542,26222,270Nov 03 04:12 PM
Thorell MarellaChief Financial OfficerNov 02Sale0.333,9991,32017,570Nov 03 04:11 PM
GILL SIMBAPresident & CEOSep 28Sale3.941,9967,86416,758Sep 29 04:02 PM
McHale DuncanChief Medical OfficerAug 08Sale9.513,43432,6577,941Aug 09 08:42 PM
Bodmer MarkCSO, President of R&DAug 08Sale9.513,12829,74716,624Aug 09 08:44 PM
Thorell MarellaChief Financial OfficerAug 08Sale9.512,00419,0589,069Aug 09 08:42 PM
GILL SIMBAPresident & CEOAug 08Sale9.513423,2523,754Aug 09 08:43 PM
Flagship Ventures Fund IV Gene10% OwnerJul 11Buy2.315,411,25512,499,9993,931,685Jul 13 05:15 PM
Bodmer MarkCSO, President of R&DMay 23Sale0.1422,5713,201262,557Jun 12 04:01 PM
Bodmer MarkCSO, President of R&DMay 08Sale0.1368,0148,536285,128May 10 09:31 PM
McHale DuncanChief Medical OfficerMay 08Sale0.1366,7308,37597,516May 10 09:32 PM
Thorell MarellaChief Financial OfficerMay 08Sale0.1338,5314,83691,469May 10 09:31 PM
GILL SIMBAPresident & CEOMay 08Sale0.133,53744458,512May 10 09:31 PM
CARRIERE STEPHEN JPrincipal Accounting OfficerJan 23Sale1.06151160203Jan 23 05:35 PM